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CORTICOSPINAL EXCITABILITY as measured by transcranial magnetic stimulation (TMS) serves as a representation of the summed excitabilities of the central and peripheral nervous systems and muscle fibers. Corticospinal excitability is associated not only with the voluntary activation of the motor cortex (24, 35, 36) , but also with the plasticity of the primary motor cortex (29, 30) . Accordingly, identification of physiological pathways and interventions that enhance corticospinal excitability in humans is an important research topic.
Pharmacological interventions that influence the concentration or function of neuromodulatory monoamines (e.g., norepinephrine, dopamine) have demonstrated consistent alterations in corticospinal excitability in healthy humans (2, 16, 21, 31, 32) . Corticospinal excitability is most often measured as the size of motor-evoked potential (MEP) in response to a single pulse of TMS to the primary motor area in humans in vivo (42) . Norepinephrine agonists increase the size of the MEP in humans (2, 16, 21, 31, 32) . In contrast, dopamine agonist suppresses MEP (21) . Thus, the modulating role of norepinephrine and dopamine in corticospinal excitability is supported by pharmacological interventions. However, the functional involvement of the monoaminergic influence on corticospinal excitability in physiological conditions is unknown.
In physiological conditions, the release of norepinephrine and dopamine in the brain is increased with physiological stresses (e.g., hemodynamic stress) associated with the heightening of sympathetic nerve activity (SNA) (7, 15, 17, 19, 27, 39, 43, 44) . In human research on autonomic regulations, an application of hemodynamic stress by means of the lower body negative pressure (LBNP) procedure is an established and commonly used physiological intervention for heightening SNA in a well controlled manner (6, 9, 15, 33, 37, 38, 40, 41) . The LBNP procedure is regarded as a human model for acute central hypovolemia, causing baroreceptor unloading, which invokes immediate reflex responses involving the heightening of SNA (6) . Evidence demonstrates increased central release of norepinephrine and dopamine in response to hemodynamic stress, including baroreceptor unloading, in animal experiments (7, 17, 19, 27, 39, 43, 44) . Therefore, the LBNP procedure was employed in the current study to physiologically induce central hypovolemia and increase SNA in humans.
The purpose of this study was to investigate the effects of physiological heightening of SNA on corticospinal excitability. To accomplish this, the size of MEP was compared between physiological conditions with and without the application of LBNP in healthy human adults. While norepinephrine and dopamine agonists enhance and suppress corticospinal excitability (2, 16, 21, 31, 32) , respectively, administration of agents that simultaneously facilitate the dopaminergic and noradrenergic systems has been shown to enhance corticospinal excitability (2, 16) , probably by a mechanism that influences the noradrenergic system. It was therefore hypothesized that the size of MEP will be greater with the application of LBNP.
METHODS
Subjects. Twenty-one healthy adults (20.6 Ϯ 1.6 years of age, 9 women) were randomly assigned to either the experimental (n ϭ 12) or control (n ϭ 9) group. All subjects were right-handed, as confirmed with the Edinburgh handedness inventory (Table 1) (28) . Volunteers were free of any signs of chronic altered SNA, with no history of diabetes, cardiovascular problems, brain or nerve disorder, obesity, hypertension, or hypotension (23). Subjects did not perform extensive hand grip activity, exhibit skilled use of hands, report arthritis of the hands, or take any medication that might affect motor control or brain and nerve function, or a combination thereof. In addition, subjects were not allowed to participate if they had a family history of seizure or epilepsy, skin allergies, were pregnant, prone to severe headaches, or had metal in their head other than dental fillings (20) . To minimize the variability in the basal physiologic level and responsiveness of SNA across subjects, all experiments were conducted at 8:00 am; participants abstained from food and drink with the exception of water for 10 h prior to the experiment (1). Women were tested during their follicular phase to avoid potential confounding effects of estrogen and progesterone (26) . All subjects gave written informed consent. Local institutional review boards approved the study.
Experimental approach. MEP of the resting first dorsal interosseus (FDI) muscle was measured in both groups. In the experimental group, MEP was recorded at 0 mmHg LBNP (basal SNA) in trial 1 and at 40 mmHg LBNP (heightened SNA) in trial 2. The two trials were separated by 1 h. The experimental protocol did not incorporate the testing at heightened SNA preceding the testing at basal SNA to avoid interference of any possible carryover effects of the LBNP procedure. To account for possible effects of order, the control group went through the same study procedure as the experimental group, except MEP was measured at 0 mmHg LBNP (basal SNA) in both trial 1 and trial 2. Effects of heightened SNA on corticospinal excitability were assessed as the difference in MEP size between trial 1 and trial 2, compared between the two groups.
Sympathetic nerve activity modulation. SNA was modulated using the LBNP procedure. Participants lay supine with their lower body inside the LBNP chamber (1.2 ϫ 0.6 ϫ 0.5 m). Subjects wore a neoprene belt about their hips at the level of the iliac crest. An airtight, flexible nylon cover was fit over the opening of the LBNP chamber to form a seal between the chamber and the belt. A bicycle saddle in the chamber prevented subject displacement during the application of LBNP. A commercial vacuum (Dayton Industrial, Dayton, OH) attached to the chamber was used to lower the pressure inside the chamber. The LBNP was adjusted with a valve between the vacuum and the chamber. This setup has been used repeatedly in LBNP studies by Seals and colleagues (9, 37, 41) . During trial 2 in the experimental group, the pressure in the chamber was gradually reduced to Ϫ40 mmHg relative to ambient pressure in 20 s. LBNP of 40 mmHg is known to significantly and substantially increase plasma norepinephrine concentration (15) and heart rate with little changes in blood pressure (38) . The vacuum remained on during the recording of MEPs across trials including when the valve was closed at 0 mmHg LBNP (trial 1 in the experimental group and trial 1 and trial 2 in the control group). Blood pressure at the brachial artery in the left arm and heart rate (averaged over 5-7 s) at the fingertip were monitored noninvasively (Cardiocap/5, GE Healthcare, Giles, UK) and recorded at each TMS intensity, 30 s into the block. Measurement of blood pressure took ϳ30 s.
Corticospinal excitability. Corticospinal excitability was assessed noninvasively with single-pulse TMS (Magstim 200 2 by way of the BiStim module, Magstim, Whitland, Wales, UK) of the left primary motor cortex. The head was oriented in neutral position on a pillow; the arms lay at the subjects' sides with the right hand resting on the bed in pronation. The subjects were instructed not to move their arms or hands during measurement. The orientation of the right hand was monitored visually throughout the experiment.
The experiment was conducted in an electrically shielded room. A surface electromyogram (EMG) was recorded using two Ag-AgCl electrodes (E224A, IVM, Healdsburg, CA) placed on the skin overlying the right FDI in a belly-tendon montage. One electrode was placed over the belly of the FDI muscle and the other was attached to the skin over the base of the proximal phalanx of the index finger, after abrasion of the skin. A wet circumferential strap electrode (F-E10SG1, Grass Technologies, West Warwick, RI) was placed around the right wrist for a reference. The EMG was differentially preamplified 300 times (Y03-000, Motion Laboratories, Cortlandt Manor, NY) and further amplified with a custom-built amplifier for a total gain of 1,000.
A figure-eight coil (second-generation double 70-mm remote coil, Magstim) was held over the left primary motor cortex at the optimum position (i.e., the hot spot) for eliciting an MEP in the resting FDI muscle of the right hand. The coil was held with the handle pointing posteriorly at an angle of ϳ45°to the sagittal plane yielding an E-field perpendicular to the central sulcus (4) . A TMS coil navigation system (NDI TMS Manager, Northern Digital, Waterloo, ON, Canada) was used to maintain the coil position in three-dimensional space relative to the head. The data were sampled at 5,000 samples/second with an analog-to-digital converter (Power 1401, Cambridge Electronic Design, Cambridge, UK) and data acquisition software (Signal 4.0, Cambridge Electronic Design) for on-line monitoring and storage, and off-line analysis. Visual feedback of the prestimulus EMG was provided to ensure relaxation of the FDI.
The resting motor threshold (RMT) was determined as the smallest TMS intensity needed to elicit an MEP with peak-to-peak amplitude (PPamp) greater than 50 V in 5 out of 10 consecutive stimulations (5, 8) . RMT was measured as a percentage of maximal stimulator output for each subject at basal SNA with the vacuum turned off. Previous studies show that the effects of norepinephrine or dopamine agonists on corticospinal excitability may depend on TMS intensity (2, 16, 21, 31, 32) . Therefore, MEPs were collected in response to six intensities of TMS (i.e., 90, 100, 110, 120, 130, and 140% of RMT) in each subject. Measurements were made in blocks, with 12 MEP responses per block (i.e., per TMS intensity), and the order of the TMS intensity blocks was randomized. In trial 1, MEPs were collected at ambient pressure (0 mmHg LBNP) in both groups. One hour later, in trial 2, MEPs were again collected at ambient pressure in the control group and at 40 mmHg LBNP in the experimental group.
M-wave (supplemental experiment).
After completing the TMS data analysis, a supplemental experiment was performed in a separate group of three subjects to explore the effect of LBNP on the compound muscle action potential (M-wave) of the FDI. These subjects were tested on 2 days separated by at least 1 wk in the same experimental setup as for the TMS experiment. On the experimental day, the M-wave was measured at 0 mmHg (trial 1) followed by 40 mmHg (trial 2). On the control day, the M-wave was recorded at 0 mmHg in both trials. The two trials were separated by 1 h, and the testing days were randomized. Electrical stimulation was delivered to the ulnar nerve transcutaneously via two stimulating electrodes at the wrist using a constant current stimulator (Digitimer DS7AH, Digitimer Limited, Herdfordshire, UK). Three levels of submaximal stimulation intensities were set to elicit target M-wave PPamps within the range of 1 to 3 mV in trial 1. The target amplitudes were chosen to approximately cover the amplitude range of the MEP observed during the TMS at higher intensities. Supramaximal M-wave was also collected at 150% of stimulation intensity for the maximal M-wave. Twenty-five stimulations were delivered at each intensity, separated by 10 s. The supramaximal M-wave was collected first, followed by the submaximal M-waves, in random order.
Data reduction. The first two MEP responses in each block were discarded to control for any possible startle responses. All remaining recordings were inspected, and recordings that showed obvious prestimulus EMG activity 100 ms preceding the TMS were discarded by visual inspection. The MEP PPamp, the area bound by the MEP and the 0 mV axis (MEP area), and the root mean square (RMS) amplitude of the prestimulus EMG were calculated for each response (Fig. 1) . Figure 1 shows EMG recordings from trial 1 and trial 2 of two representative subjects, one from the experimental group (top row) Baseline measurements prior to trial 1 measurements. Values are mean Ϯ SD; no significant effect (P Ͼ 0.05).
and one from the control group (bottom row). The EMG in the period between 20 and 50 ms following application of TMS was used to measure MEP PPamp and MEP area. In addition to PPamp, MEP area was analyzed to account for potential changes in MEP that might not have been reflected in PPamp. The RMS amplitude of the prestimulus EMG was calculated from data 100 ms preceding the application of TMS. Values in each response were averaged together within each intensity block.
As a supplemental assessment for exploring the potential alteration in the association between MEP and TMS intensity, the linear phase of MEP stimulus-response curve was approximated with the standardized slope of the regression line through the middle four intensities (100 -130% RMT). The standardized regression slope was calculated by dividing the slope of a regression line by the ratio of the standard deviations of each variable using SPSS software (IBM, Armonk, NY). The standardized regression slope was used because it accounts for differences in the distribution of variables.
M-wave data were analyzed in a similar way that MEP data were analyzed. The first two responses at each intensity of stimulation were discarded to control for possible startle effects. Recordings that showed obvious prestimulus EMG activity 100 ms preceding the stimulation were discarded. For the remaining responses, the M-wave PPamp between 3 and 25 ms following stimulation were averaged at each intensity. The relative change in M-wave PPamp from trial 1 to trial 2 was calculated by subtracting the trial 1 value from the trial 2 value and dividing it by the trial 1 value.
Statistical analysis. Subject characteristics included age, handedness index, baseline heart rate, baseline mean blood pressure, and RMT. The baseline heart rate, baseline mean blood pressure, and heart rate were measured with the vacuum turned off before trial 1. These variables were compared between the two groups with a Student's independent samples t-test. The main dependent variables for corticospinal excitability were MEP PPamp and MEP area. The independent variables were group (control and experimental), trial (trial 1 and trial 2), and intensity (90 -140% RMT). To test the effects of physiologically heightened SNA on corticospinal excitability, a three-factor (group, trial, intensity) ANOVA with repeated measures for trial and intensity was used. A significant three-factor interaction with significant differences between trial 1 and trial 2 in the experimental group would indicate effects of LBNP on MEP PPamp and MEP area. Standardized slope of the regression line was analyzed with a twofactor (group, trial) ANOVA with repeated measures for trial. RMS amplitude of the prestimulus EMG, heart rate, and mean arterial blood pressure were analyzed with a three-factor (group, trial, intensity) ANOVA with repeated measures to test for differences in prestimulus muscle activation and measures of sympathetic nerve activity. Inclusion of the control group in the ANOVAs ensured that any differences observed between trial 1 and trial 2 in the experimental group were not due to an order effect. An alpha level of 0.05 was used for all significance testing and P Ͼ 0.05, P Ͻ 0.05, and P Ͻ 0.01 were noted where appropriate. In all repeated measures ANOVA models, the Mauchly Test of Sphericity for interaction was found to be significant. All P values were adjusted using the Huynh-Feldt Epsilon correction factor. Significant interactions were tested with the Bonferroni post hoc test. Statistical analyses were performed using Statistica 9.0 (StatSoft, Tulsa, OK). Unless stated otherwise, the data are presented as mean Ϯ SD in the text and tables and as mean Ϯ standard error of mean in the figures.
RESULTS
Basic subject characteristics including age, handedness index, baseline heart rate, baseline mean blood pressure, and RMT were not significantly different between the groups (P Ͼ 0.05, Table 1 ). Prestimulus EMG did not significantly vary with intensity, trial, or group (P Ͼ 0.05). Prestimulus EMG values were 3.60 Ϯ 0.17 V and 3.62 Ϯ 0.12 V in trial 1 and trial 2 in the control group, and 3.78 Ϯ 1.29 V and 3.77 Ϯ 1.26 V in trial 1 and trial 2 in the experimental group, respectively. In the control group, heart rate was 60.0 Ϯ 7.1 and 61.8 Ϯ 6.9 beats/min in trial 1 and trial 2, respectively. In the experimental group, heart rate increased from 60.0 Ϯ 7.0 beats/min in trial 1 to 70.4 Ϯ 9.2 beats/min in trial 2. After detecting the significant effect of trial (P Ͻ 0.01) and group ϫ trial interaction (P Ͻ 0.01), post hoc testing revealed that heart rate increased significantly from trial 1 to trial 2 only in the (Fig. 2) . The MEP PPamp was influenced by stimulus intensity (P Ͻ 0.01); trial (P Ͻ 0.01); their interaction (P Ͻ 0.01); and an interaction of group, trial, and stimulus intensity (P Ͻ 0.01). Post hoc testing showed the MEP PPamp in trial 2 was greater than in trial 1 only at 130% RMT (by 42%, P Ͻ 0.01) and 140% RMT (by 19%, P Ͻ 0.05) in the experimental group (Fig. 2, left) , but not in the control group (Fig. 2, right) . The standardized slope of the linear regression of the MEP PPamp was not significantly influenced by group or trial, but had a significant group ϫ trial interaction (P Ͻ 0.05). The slope was 0.673 Ϯ 0.147 and 0.619 Ϯ 0.154 in trial 1 and trial 2, respectively, in the control group, and 0.610 Ϯ 0.184 and 0.727 Ϯ 0.144, in trial 1 and trial 2, respectively, in the experimental group. Although the post hoc test did not detect statistical significance, the slope showed a trend for a 19% increase in MEP PPamp from trial 1 to trial 2 in the experimental group, on average.
The elicited M-wave PPamps at each intensity were 1.4 Ϯ 0.3, 2.0 Ϯ 0.2, 2.9 Ϯ 0.6, and 18.5 Ϯ 6.3 mV when averaged across trials, days, and subjects. The changes in M-wave PPamp from trial 1 to trial 2 were variable with no clear trend of consistent increase or decrease on the experimental day. The relative changes in M-wave PPamp from trial 1 to trial 2 in each subject were Ϫ19.9 Ϯ 14.6% vs. Ϫ9.0 Ϯ 31.7%, 9.5 Ϯ 6.7% vs. Ϫ3.4 Ϯ 9.2%, and Ϫ11.3 Ϯ 5.3% vs. 13.3 Ϯ 11.1% for control vs. experimental days, respectively, when averaged across intensities. When further averaged across subjects, the relative change in M-wave PPamp between trial 1 and trial 2 was Ϫ7.2 Ϯ 15.6% on the control day and 0.3 Ϯ 20.7% on the experimental day.
DISCUSSION
The main findings are the significant increases in the MEP PPamp during the application of LBNP compared with ambient pressure at 130% and 140% RMT TMS intensity in the experimental group.
The influence of heightened SNA on MEP size was examined between trials with and without LBNP in the experimental and control groups, respectively. The miniscule level of prestimulus EMG was consistent across groups and trails, which indicates that all subjects maintained a resting state across measurements. Significantly greater MEP size at 130% and 140% RMT in trial 2 (with LBNP) compared with trial 1 (no LBNP) in the experimental group indicated increased corticospinal excitability with LBNP. This indication was strengthened by the significant group ϫ trial interaction for the standardized slope of the MEP size.
Heightening of SNA with LBNP in the experimental group was supported by cardiovascular measurements. In response to LBNP, heart rate increased significantly, while there was little change in mean arterial blood pressure. The mild increase in heart rate with little change in blood pressure has been observed using similar LBNP procedures (see Ref. 14 for review). The LBNP procedure is a commonly used intervention that is regarded as a human model for acute central hypovolemia (6), reducing central venous pressure. The drop in central venous pressure is sensed by baroreceptors, resulting in the heightening of SNA via the baroreflex response (3, 40) . Heightened SNA increases heart rate, cardiac contractility, and peripheral resistance of the cardiovascular system to maintain mean arterial blood pressure (3). In animal ex- TMS Intensity (% RMT) ** * Fig. 2 . Motor-evoked potential (MEP) peakto-peak amplitude in two trials as a function of transcranial magnetic stimulation (TMS) intensity in the experimental and control groups. Square and diamond symbols indicate measurements taken during trial 1 and trial 2, respectively. LBNP of 40 mmHg was applied during trial 2 (filled diamonds) in the experimental group (left). MEP was enhanced with LBNP in the experimental group. *P Ͻ 0.05, **P Ͻ 0.01 between trials at the corresponding intensity, revealed by post hoc test of the group ϫ trial ϫ intensity interaction. RMT, resting motor threshold.
periments, norepinephrine and dopamine release at the locus caeruleus is enhanced with mild hypovolemia or a fall in blood pressure (17, 39) . Unfortunately, it is technically impossible to directly assess the central concentration of norepinephrine and dopamine in humans in vivo. Nonetheless, due to the neural projection from the locus caeruleus to the neocortex (10, 12) , it is reasonable to infer that concentrations of norepinephrine and dopamine within the neocortex (including the motor cortex) were increased due to LBNP in the current study. Collectively, the observed response in heart rate and mean blood pressure in the experimental group indirectly corroborates the heightening of SNA with LBNP that presumably induced physiological increases in monoamine concentrations. The influences of monoamines on corticospinal excitability may be inferred by comparing the current physiological results with previous studies using pharmacological agents for norepinephrine and dopamine in healthy humans. Administration of yohimbine and reboxetine, both noradrenaline facilitating agents, increase corticospinal excitability at and above 130% and 150% RMT TMS intensity, respectively (31, 32) . Below these TMS intensities, MEP amplitude appears unaffected by these agents (31, 32) . Hence norepinephrine plays a role in enhancing corticospinal excitability. In contrast, dopamine appears to have an opposite influence on corticospinal excitability. Dopamine agonists such as bromocriptine and cabergoline, dopamine D2 and D2/D3 receptor agonists, respectively (13, 25) , increase intracortical inhibition (21, 45) . In line with increased intracortical inhibition, cabergoline has been shown to decrease corticospinal excitability at TMS intensities at and above 120% RMT (21) .
Under the conditions in which both norepinephrine and dopamine are manipulated, observed changes in corticospinal excitability reflect the net results of opposing influences from the two monoamines. For example, methylphenidate and D-amphetamine are both indirect agonists of the dopamine and norepinephrine systems. While both agents have similar effects on norepinephrine function, the latter agent has a much greater influence (10-fold at threshold levels) on dopamine function compared with the former (22) . Both agents increase corticospinal excitability. Methylphenidate does so starting at a TMS intensity of ϳ135% RMT (16) . On the other hand, TMS intensity needs to exceed 150% RMT before any facilitatory effects of D-amphetamine on corticospinal excitability can be observed (2) . It is likely that enhanced corticospinal excitability at high TMS intensities due to norepinephrine was little influenced by moderate changes in dopamine with methylphenidate (16) but was overshadowed by the opposite influence from much augmented dopamine function with D-amphetamine (2) . Hemodynamic stress is known to physiologically increase the central release of both norepinephrine and dopamine (7, 17, 19, 27, 39, 43, 44) , although its quantification in humans in vivo is technically impossible. Nonetheless, the above-mentioned consistent evidence collectively suggests that the current increase in corticospinal excitability at 130% and 140% RMT with hemodynamic stress (Fig. 2 ) most likely reflects facilitatory effect of norepinephrine and relatively minor influence from dopamine.
The enhancement of MEP at higher TMS intensities appears to be a common characteristic of the influence of increased noradrenergic function on corticospinal excitability. Corticospinal excitability assesses the integrity of the entire corticospinal tract, from the motor cortex down to the muscle, and can be facilitated anywhere along this tract. Administration of norepinephrine agonists in humans has shown no systematic change in the profiles of maximum M-wave, F-wave, or Hreflex (2, 16, 31, 32) , measures of excitability at the neuromuscular junction, limited motor unit pool, and partial motor unit pool excitability, respectively, at the spinal cord. Facilitation of SNA with various physiological or psychological interventions does not induce a systematic change in the H-reflex amplitude (18, 34) . On the basis of these previous and current studies, it is tempting to suggest that the LBNP increases MEP with enhanced noradrenergic function due to physiological heightening of SNA and that the involvement of spinal mechanisms is less likely. However, the applicability of previous findings to the current results needs to be considered with caution due to differences in experimental protocols. Nonetheless, in our supplemental experiment employing the same LBNP protocol as was used for recording MEP, no clear trend of consistent change was observed in M-wave amplitude due to 40 mmHg LBNP. Hence the mechanisms responsible for the increased MEP amplitude with LBNP most likely appear to be proximal to the neuromuscular junction. More detailed identification of the specific location influenced by physiological heightening of SNA is beyond the scope of the current human study and would warrant a new set of targeted vigorous experiments in humans or animals.
Facilitation of MEP at higher TMS intensities provides possibilities that higher TMS intensity is needed to either directly reach (e.g., depth-wise) or activate the populations of neurons most responsive to upregulated noradrenergic function in the cortex. At the motor cortex, increased monoamine concentration may modulate the responsiveness of corticospinal tract neurons or interneurons, such as the inhibitory ␥-aminobutyric acid interneurons and facilitatory N-methyl-D-aspartic acid interneurons. TMS activates the corticospinal tract transsynaptically by depolarizing the axons of interneurons that synapse onto the tract neurons (11) . As TMS intensity increases, more interneurons are recruited (11) . The indifferent MEP response to 90 -110% RMT TMS intensity with the manipulation of SNA (Fig. 2) and monoamines (2, 16, 31, 32) indicates that the excitability of the corticospinal tract neurons and the low-threshold interneurons remains unaffected. Increased excitability of higher-threshold interneurons would, then, be one of the mechanisms underlying the enhanced MEP at higher TMS intensities due to increased norepinephrine with pharmacological agents and likely with acute mild central hypovolemia induced by LBNP.
The finding that physiologically heightened sympathetic nerve activity increases corticospinal excitability has functional implications in several aspects. Corticospinal excitability can influence the probability and amount of muscle activity for the same motor command, regardless of the status of muscle contraction or relaxation. In situations in which sympathetic nerve activity is acutely increased physiologically (e.g., with orthostatic stress, cold stress, postexercise ischemia), individuals may tend to have unintended contraction or greater contraction than intended. On the positive side, increased corticospinal excitability may allow individuals to produce greater muscle force and more rapid movement with less effort. On the negative side, increased corticospinal excitability may lead to an earlier onset and delayed offset of movement execution than intended, increased antagonist co-contraction, and an overall decrease in motor control. If the acute effect of phys-iologically heightened SNA persists in a chronic time frame, it is possible that increased corticospinal excitability might influence motor control in individuals with clinical populations who potentially have physiological heightening of sympathetic nerve activity (e.g., hypertension, sleep apnea, stroke, heart failure). Examinations of the functional implications and applicability to chronic time frame warrant future studies.
In conclusion, corticospinal excitability was enhanced with physiologically heightened sympathetic nerve activity by means of lower body negative pressure.
